Rapport Therapeutics (RAPP) CDO sells 404 shares in plan

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold 404 shares of common stock on 2026-08-19 at $49.90 per share in an open-market transaction. After this sale, the officer directly held 246,022 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Insider Trade Summary 10b5-1

Net Seller: 404 shares

Net Sell 1 txn

Insider Yeleswaram Krishnaswamy

Role Chief Development Officer

Sold 404 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	404	$49.90	$20K

Holdings After Transaction: Common Stock — 246,022 shares (Direct)

Footnotes (1)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Key Figures

Shares sold: 404 shares Sale price per share: $49.90 per share Shares held after transaction: 246,022 shares +1 more

4 metrics

Shares sold 404 shares Common Stock sale on 2026-08-19

Sale price per share $49.90 per share Common Stock transaction on 2026-08-19

Shares held after transaction 246,022 shares Direct ownership following the 2026-08-19 sale

Net shares sold 404 shares Net of all reported buy/sell transactions in this Form 4

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction market

"transaction code description: Sale in open market or private transaction"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What insider transaction did RAPP disclose in this Form 4?

Rapport Therapeutics disclosed that Chief Development Officer Krishnaswamy Yeleswaram sold 404 shares of common stock on 2026-08-19 at $49.90 per share in an open-market transaction under a Rule 10b5-1 trading plan.

How many RAPP shares did the insider sell and at what price?

The insider sold 404 shares of Rapport Therapeutics common stock at a price of $49.90 per share in a sale classified as an open-market or private transaction.

How many RAPP shares does the reporting person hold after this transaction?

Following the reported sale, Chief Development Officer Krishnaswamy Yeleswaram directly held 246,022 shares of Rapport Therapeutics common stock, as reported in the Form 4 filing.

Was the RAPP insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sale was pre-arranged under that plan.

Does this RAPP Form 4 report any derivative security transactions?

No. The Form 4 reports only a non-derivative transaction in Common Stock, with no derivative security transactions listed in the derivative transaction or derivative summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:09 PM Accepted by SEC EDGAR 08/20/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S(1)		404	D	$49.9	246,022	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

	/s/ Troy Ignelzi, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)